Literature DB >> 12441848

Ocular manifestations of hepatitis C virus infection.

Michael E Zegans1, William Anninger, Christopher Chapman, Stuart R Gordon.   

Abstract

Approximately 3.6 million persons in the United States are infected with the hepatitis C virus (HCV), a condition with both hepatic and extrahepatic sequelae. Although no pathognomonic manifestation of HCV infection in the eye has been demonstrated, associations between HCV infection and various ocular syndromes have been reported in small case series and individual patients. At this time, the ocular manifestations of HCV infections best supported by the literature include a dry eye syndrome similar to Sjögren syndrome, and ischemic retinopathy caused by either an HCV-induced vasculitis or treatment with interferon. Patients with diabetes seem to be more susceptible to interferon retinopathy and to subsequent permanent visual loss. There have been no cases of HCV transmission via corneal transplantation, suggesting that current cadaveric screening protocols are effective in preventing this route of transmission. Screening for HCV should be considered in patients with risk factors for HCV infection who suffer from unexplained ischemic retinopathy or dry eyes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441848     DOI: 10.1097/00055735-200212000-00014

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  16 in total

1.  c-Jun NH2-terminal kinase mediates interleukin-1beta-induced inhibition of lacrimal gland secretion.

Authors:  Driss Zoukhri; Elizabeth Macari; Sun H Choi; Claire L Kublin
Journal:  J Neurochem       Date:  2005-11-21       Impact factor: 5.372

Review 2.  Hepatitis C as a systemic disease: virus and host immunologic responses underlie hepatic and extrahepatic manifestations.

Authors:  Chiaki Okuse; Hiroshi Yotsuyanagi; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2007-11-22       Impact factor: 7.527

3.  Peripheral ulcerative keratitis as the presenting feature of systemic rheumatoid vasculitis without joint involvement.

Authors:  Peter J Morgan-Warren; Simon Dulku; Jaya Ravindran; George Smith
Journal:  Int Ophthalmol       Date:  2014-08       Impact factor: 2.031

4.  Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon.

Authors:  Michael R Narkewicz; Philip Rosenthal; Kathleen B Schwarz; Arlene Drack; Todd Margolis; Michael X Repka
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-08       Impact factor: 2.839

Review 5.  Oculo-renal disorders in infectious diseases.

Authors:  Hassane Izzedine; Irina Buhaescu; Bahram Bodaghi; Valerie Martinez; Eric Caumes; Phuc Lehoang; Gilbert Deray
Journal:  Int Ophthalmol       Date:  2006-03-07       Impact factor: 2.031

6.  Cystoid macular edema and visual loss as sequelae to interferon alpha treatment of systemic hepatitis C.

Authors:  Hiten G Sheth; Michel Michaelides; Dilani Siriwardena
Journal:  Indian J Ophthalmol       Date:  2010 Mar-Apr       Impact factor: 1.848

Review 7.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

8.  Ophthalmological implications of the chronic infections with the hepatitis C Virus.

Authors:  Alexa Anisia-Iuliana; Cantermir Alina; Ciuntu Roxana Elena; Chiseliţă Dorin
Journal:  Rom J Ophthalmol       Date:  2015 Oct-Dec

9.  Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C.

Authors:  Damien Sene; Valerie Touitou; Bahram Bodaghi; David Saadoun; Gabriel Perlemuter; Nathalie Cassoux; Jean-Charles Piette; Phuc-Le Hoang; Patrice Cacoub
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

10.  Increased Risk of Age-Related Macular Degeneration with Chronic Hepatitis C Virus Infection: A Nationwide Population-Based Propensity Score-Matched Cohort Study in Taiwan.

Authors:  Chih-Ching Yeh; Meei-Maan Wu; Chia-Min Wu; Fung-Chang Sung; Chih-Hsin Muo; Arlene Te; Fu-Hsiung Su
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.